CD73 recombinant proteins and antibodies

CD73, also known as ecto-5′-nucleotidase or 5′-nucleotidase (5′-NT), is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein encoded by the NT5E gene. CD73 is present on the surface of multiple cell types, including endothelial cells, lymphocyte subtypes, stromal cells, and certain types of tumor cells. CD73 is essential for the generation of extracellular adenosine from 5′-adenosine monophosphate (5′-AMP) and is an important component of the purinergic signaling pathway, which is carried out through the cooperative action of CD39.

In recent years, the purinergic signaling pathway has emerged as an important player in cancer progression, with extracellular ATP, ADP, and adenosine as major signaling molecules. Adenosine, an immunosuppressive metabolite, is a component of the tumor microenvironment (TME). As the main enzyme catalyzing adenosine production, CD73 is crucial in suppressing adequate antitumor immune responses mainly through the production of adenosine, but also promotes cancer cell proliferation, tumor growth, angiogenesis, and metastasis. More CD73 signaling pathways >>

More and more studies have shown that CD73 is a key regulatory molecule for cancer cell proliferation, migration and invasion (in vitro), tumor angiogenesis and tumor immune escape (in vivo). Based on these effects, CD73 has become an attractive therapeutic target. According to incomplete statistics, there are 89 drugs targeting CD73 worldwide.

To assist in the development of CD73 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for HER3 targets. Products include active proteins, reference antibodies and flow-validated monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization and affinity maturation services. In addition, to accelerate the development of CD73 biotherapies, DIMA BIOTECH has also prepared a CD73 target single B cell seed library, and lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD73 lead molecules, and customers can get the molecules for functional evaluation and verification the next day.